Friday 6 November 2026
Export ABT’s income statement to Excel — free account
Abbott Laboratories
ABT Healthcare Medical Devices
Abbott Laboratories' revenue for fiscal 2025 (year ended December 2025) was $44.3 billion, up 5.67% from fiscal 2024.
- Revenue
- +14.5%
- EPS
- −43.6%
- Free cash flow
- +28.9%
- Total debt
- +142.7%
Quarter to September 2026, against a year earlier
110.08
3.52
−3.10%
Follow ABT
Alert me
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
41.99 | 226.12 | 54.38 | 42.17 | 43.80 | 35.72 | 28.03 | 33.70 | 14.79 | 33.68 |
Piotroski F-Score |
5 | 4 | 7 | 7 | 6 | 8 | 6 | 6 | 7 | 5 |
P/S ratio |
2.77 | 3.73 | 4.16 | 4.81 | 5.61 | 5.80 | 4.40 | 4.77 | 4.69 | 4.92 |
Altman Z-Score |
2.79 | 2.36 | 3.34 | 3.83 | 4.34 | 5.53 | 4.85 | 5.04 | 5.27 | 5.61 |
Altman Z″-Score (non-manufacturers) |
5.16 | 2.85 | 2.99 | 3.05 | 3.39 | 4.06 | 4.19 | 4.24 | 4.72 | 4.85 |
P/FCF ratio |
27.70 | 23.07 | 25.92 | 34.14 | 33.91 | 28.89 | 24.61 | 37.78 | 30.99 | 29.50 |
Beneish M-Score |
(2.95) | (2.05) | (2.71) | (2.59) | (2.56) | (2.66) | (2.68) | (2.47) | (2.09) | (2.50) |
P/Operating CF |
49.30 | 62.37 | 72.04 | 63.56 | 51.11 | 81.45 | 82.59 | 62.92 | 68.62 | 65.80 |
Dividend Safety Score |
— | — | — | — | — | — | — | — | — | 62 |
P/B ratio |
2.78 | 3.29 | 4.14 | 4.91 | 5.88 | 6.93 | 5.21 | 4.92 | 4.11 | 4.13 |
Price to Tangible BV |
6.79 | 0.00 | 0.00 | 0.00 | 0.00 | 4,626.18 | 52.60 | 30.18 | 10.85 | 9.40 |
EV/Sales |
2.86 | 4.40 | 4.66 | 5.25 | 5.94 | 5.98 | 4.55 | 4.95 | 4.84 | 5.01 |
EV/EBITDA |
13.11 | 21.90 | 20.47 | 22.18 | 23.67 | 21.53 | 17.09 | 20.42 | 20.21 | 19.89 |
EV/Operating CF |
18.60 | 21.62 | 22.61 | 27.28 | 26.01 | 24.46 | 20.74 | 27.34 | 23.72 | 23.22 |
EV/FCF |
28.62 | 27.15 | 29.03 | 37.21 | 35.90 | 29.79 | 25.46 | 39.24 | 31.96 | 30.04 |
Quick Ratio |
3.31 | 1.67 | 1.03 | 0.88 | 1.14 | 1.28 | 1.06 | 1.00 | 1.05 | 1.02 |
Current Ratio |
4.02 | 2.26 | 1.62 | 1.44 | 1.72 | 1.85 | 1.63 | 1.64 | 1.67 | 1.58 |
Net Debt/EBITDA |
0.42 | 3.29 | 2.20 | 1.83 | 1.31 | 0.65 | 0.57 | 0.76 | 0.61 | 0.36 |
Debt/Assets |
39.27% | 36.35% | 28.83% | 26.42% | 25.55% | 24.00% | 22.53% | 20.05% | 17.35% | 14.91% |
Debt/Equity |
1.00 | 0.89 | 0.63 | 0.57 | 0.56 | 0.50 | 0.45 | 0.38 | 0.29 | 0.25 |
Asset Turnover |
0.44 | 0.42 | 0.43 | 0.47 | 0.49 | 0.58 | 0.58 | 0.54 | 0.54 | 0.53 |
Operating CF/Net income |
2.29 | 11.68 | 2.66 | 1.66 | 1.76 | 1.49 | 1.38 | 1.27 | 0.64 | 1.47 |
Capex/Depreciation |
(0.74) | (0.29) | (0.42) | (0.54) | (0.65) | (0.53) | (0.54) | (0.68) | (0.69) | (0.70) |
Interest Coverage |
7.02 | 1.73 | 4.42 | 6.76 | 9.81 | 15.81 | 14.99 | 10.17 | 12.21 | 16.33 |
| 6.66% | 1.84% | 7.66% | 11.89% | 13.98% | 20.49% | 19.01% | 15.11% | 30.91% | 12.96% | |
| 2.98% | 0.74% | 3.30% | 5.46% | 6.40% | 9.57% | 9.27% | 7.75% | 17.33% | 7.76% | |
ROIC |
8.36% | 1.99% | 4.96% | 6.28% | 7.54% | 12.02% | 12.01% | 8.76% | 7.89% | 8.87% |
Return on Tangible Assets |
5.42% | 2.53% | 17.96% | 28.71% | 25.59% | 35.19% | 36.69% | 30.15% | 66.49% | 30.61% |
Average Days of Receivables |
56.85 | 69.95 | 61.86 | 62.07 | 67.65 | 54.97 | 51.99 | 59.74 | 60.25 | 65.29 |
Research and Development Expense of Revenue |
6.94% | 8.25% | 7.52% | 7.65% | 6.99% | 6.37% | 6.62% | 6.83% | 6.78% | 6.64% |
Selling, General and Administrative Expense of Revenue |
32.30% | 33.52% | 31.87% | 30.61% | 28.02% | 26.29% | 25.77% | 27.30% | 27.88% | 27.82% |
Intangible Assets out of Total Assets |
0.23 | 0.60 | 0.63 | 0.59 | 0.53 | 0.48 | 0.45 | 0.44 | 0.37 | 0.34 |
Share Based Compensation of Revenue |
1.49% | 1.48% | 1.56% | 1.63% | 1.58% | 1.49% | 1.57% | 1.61% | 1.60% | 1.50% |
Graham Net Nets |
(0.09) | (0.24) | (0.17) | (0.14) | (0.10) | (0.06) | (0.06) | (0.06) | (0.05) | (0.04) |
Graham Number |
17.13 | 10.23 | 22.87 | 28.65 | 32.36 | 42.42 | 43.04 | 40.46 | 68.84 | 50.37 |
Earnings Yield |
2.38% | 0.44% | 1.84% | 2.37% | 2.28% | 2.80% | 3.57% | 2.97% | 6.76% | 2.97% |
Free Cash Flow Yield |
3.61% | 4.34% | 3.86% | 2.93% | 2.95% | 3.46% | 4.06% | 2.65% | 3.23% | 3.39% |
Revenue per Share |
14.12 | 15.74 | 17.39 | 18.05 | 19.52 | 24.27 | 24.90 | 23.05 | 24.11 | 25.46 |
Operating CF per Share |
2.17 | 3.20 | 3.58 | 3.47 | 4.46 | 5.93 | 5.47 | 4.17 | 4.92 | 5.49 |
Capex per Share |
(0.76) | (0.65) | (0.79) | (0.93) | (1.23) | (1.06) | (1.01) | (1.27) | (1.27) | (1.25) |
Free Cash Flow per Share |
1.41 | 2.55 | 2.79 | 2.54 | 3.23 | 4.87 | 4.45 | 2.91 | 3.65 | 4.25 |
Cash per Share |
12.71 | 5.52 | 2.32 | 2.34 | 4.03 | 5.77 | 5.80 | 4.18 | 4.58 | 5.13 |
Shareholders Equity per Share |
14.03 | 17.87 | 17.48 | 17.70 | 18.61 | 20.30 | 21.05 | 22.31 | 27.53 | 30.31 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.03 | 17.87 | 17.48 | 17.70 | 18.61 | 20.30 | 21.05 | 22.31 | 27.53 | 30.31 |
Free Cash Flow |
2,082.00 | 4,435.00 | 4,906.00 | 4,498.00 | 5,724.00 | 8,648.00 | 7,804.00 | 5,059.00 | 6,351.00 | 7,395.00 |
Working Capital |
20,116.00 | 11,235.00 | 5,620.00 | 4,804.00 | 8,534.00 | 11,134.00 | 9,735.00 | 8,829.00 | 9,499.00 | 9,500.00 |
Capital Expenditures |
(1,121.00) | (1,135.00) | (1,394.00) | (1,638.00) | (2,177.00) | (1,885.00) | (1,777.00) | (2,202.00) | (2,207.00) | (2,171.00) |
Net Current Asset Value |
(5,173.00) | (25,005.00) | (21,819.00) | (20,919.00) | (19,104.00) | (14,933.00) | (12,309.00) | (11,717.00) | (9,857.00) | (7,946.00) |
EV/EBIT |
19.69 | 76.98 | 39.02 | 36.93 | 38.36 | 30.58 | 23.76 | 30.65 | 29.74 | 27.58 |
Capex to Sales |
0.05 | 0.04 | 0.05 | 0.05 | 0.06 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 |
Price to Operating Income |
19.06 | 65.41 | 34.84 | 33.89 | 36.24 | 29.65 | 22.97 | 29.51 | 28.84 | 27.09 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.27 | 0.52 | 0.44 | 0.38 | 0.37 | 0.39 | 0.36 | 0.32 | 0.30 | 0.26 |
Cash ROIC |
3.46% | 6.48% | 9.06% | 8.43% | 9.75% | 13.44% | 12.22% | 8.32% | 9.07% | 9.91% |
Accounts Receivable Turnover |
6.26 | 6.45 | 5.86 | 6.02 | 5.85 | 6.68 | 6.87 | 6.28 | 6.22 | 5.97 |
Accounts Payable Turnover |
8.05 | 6.93 | 4.73 | 4.25 | 4.17 | 4.44 | 4.25 | 4.04 | 4.41 | 4.58 |
Inventory Turnover |
3.61 | 4.11 | 3.44 | 3.26 | 3.22 | 3.65 | 3.38 | 2.82 | 2.93 | 3.05 |
Average Days of Payables |
47.28 | 70.65 | 85.46 | 89.71 | 96.00 | 86.80 | 87.85 | 87.21 | 81.85 | 80.11 |
Days of Inventory on Hand |
97.69 | 105.92 | 109.05 | 119.06 | 121.93 | 101.54 | 117.71 | 133.41 | 120.86 | 122.58 |
Average Receivables |
3,333.00 | 4,248.50 | 5,215.50 | 5,303.50 | 5,919.50 | 6,450.50 | 6,352.50 | 6,391.50 | 6,745.00 | 7,427.00 |
Average Payables |
1,129.50 | 1,790.00 | 2,688.50 | 3,113.50 | 3,599.00 | 4,177.00 | 4,507.50 | 4,451.00 | 4,245.00 | 4,217.50 |
Average Inventory |
2,516.50 | 3,017.50 | 3,698.50 | 4,056.00 | 4,664.00 | 5,084.50 | 5,665.00 | 6,371.50 | 6,382.00 | 6,341.00 |
Average Assets |
46,956.50 | 64,458.00 | 71,711.50 | 67,530.00 | 70,217.50 | 73,872.00 | 74,817.00 | 73,826.00 | 77,314.00 | 84,063.50 |
Average Common Equity |
21,021.50 | 25,907.50 | 30,910.00 | 31,011.50 | 32,152.00 | 34,513.50 | 36,464.50 | 37,866.00 | 43,364.00 | 50,336.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026